Atrioventricular Septal Defect (AVSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Atrioventricular Septal Defect (AVSD) Market Outlook

Thelansis’s “Atrioventricular Septal Defect (AVSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrioventricular Septal Defect treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Atrioventricular Septal Defect (AVSD) Overview

Atrioventricular septal defects (AVSD) are congenital heart conditions marked by varying degrees of atrial and ventricular septal defects and a shared or partially separated atrioventricular orifice. A partial AVSD involves specific features like an atrial septal defect, separate atrioventricular valves with a common junction, a ventricular septal defect, and a cleft mitral valve. On the other hand, a complete AVSD features a common atrioventricular valve with an atrial septal defect and an unrestricted inlet-type ventricular septal defect. The clinical presentation of AVSD depends on the type of defect, the size of the intracardiac shunt, and any accompanying heart malformations. Complete AVSD patients often show signs of pulmonary congestion and right heart failure early in life due to a substantial left-to-right shunt, significantly as pulmonary vascular resistance decreases after birth. Heart failure and Eisenmenger syndrome might develop earlier in cases with atrioventricular valve regurgitation, ventricular imbalance, or aortic coarctation. Patients with partial AVSD, without complex congenital heart issues and minimal valve regurgitation, usually remain asymptomatic in early childhood and are typically diagnosed incidentally based on findings like heart murmurs and fixed splitting due to an atrial septal defect. The prognosis for untreated AVSD is bleak, with roughly 50% of patients not surviving infancy due to heart failure or pulmonary infections. Those who survive beyond the first year often develop irreversible pulmonary vascular disease and eventually, experience a reversal of the shunt. Patients who undergo surgical repair have a 90% survival rate for around 15 years, although approximately 9% to 10% of them may require reoperation within that period. Most complications related to AVSD are linked to intracardiac shunting and atrioventricular valve regurgitation. Complete AVSD leads to right-sided heart overload, heart failure, and pulmonary congestion at a young age, contributing to a significant infant mortality rate. This shunt can lead to irreversible pulmonary vascular disease, pulmonary hypertension, and Eisenmenger syndrome without correction.

• Approximately 2,118 babies (1 in 1,859 babies) are born with AVSD annually in the United States.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: